Genome Therapeutics Private Limited
Pharmaceutical company manufacturing and trading drugs, established in 2011.
2011 | Hyderabad, Telangana (India) | Active
Genome Therapeutics Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 1.00 M
- Company Age 13 Year, 7 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 6.30 M
- Revenue Growth 0.89%
- Profit Growth -22.84%
- Ebitda -77.45%
- Net Worth 27.81%
- Total Assets -1.29%
About Genome Therapeutics
Genome Therapeutics Private Limited (GTPL) is a Private Limited Indian Non-Government Company incorporated in India on 15 July 2011 and has a history of 13 years and seven months. Its registered office is in Hyderabad, Telangana, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 1.00 M.
The company currently has active open charges totaling ₹6.30 M.
Ravimohan Dhavala and Dhavala Madhavi serve as directors at the Company.
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24232TG2011PTC075543
- Company No.
075543
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
15 Jul 2011
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Pharma
Who are the key members and board of directors at Genome Therapeutics?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Dhavala Madhavi  | Managing Director | 15-Jul-2011 | Current |
Board Members (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Ravimohan Dhavala | Whole-Time Director | 15-Jul-2011 | Current |
Financial Performance of Genome Therapeutics.
Genome Therapeutics Private Limited, for the financial year ended 2020, experienced modest growth in revenue, with a 0.89% increase. The company also saw a substantial fall in profitability, with a 22.84% decrease in profit. The company's net worth Soared by an impressive increase of 27.81%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Genome Therapeutics?
In 2020, Genome Therapeutics had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
Open Charges
₹6.30 M
Satisfied Charges
₹0
Charges Breakdown by Lending Institutions
- Others : 0.63 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 08 Dec 2012 | Others | ₹6.30 M | Open |
How Many Employees Work at Genome Therapeutics?
Unlock and access historical data on people associated with Genome Therapeutics, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Genome Therapeutics, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Genome Therapeutics's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
Latest Updates, News, and FAQs on Genome Therapeutics
Recent activity within the organization
- Annual General Meeting
Genome Therapeutics Private Limited last Annual general meeting of members was held on 30 Sep 2024 as per latest MCA records.
- Balance Sheet
Genome Therapeutics Private Limited has filed its annual Financial statements for the year ended 31 Mar 2024 with Roc Hyderabad.
- Charges
A charge with Others of Rs. 6.30 M registered on 08 Dec 2012 with Charge ID 10446105 was modified on 23 Jun 2016.
- Charges
A charge with Others amounted to Rs. 6.30 M with Charge ID 10446105 was registered on 08 Dec 2012.
- Director Appointment
Ravimohan Dhavala was appointed as a Whole-Time Director was appointed as a Whole-Time Director on 15 Jul 2011 & has been associated with this company since 13 years 7 months .
- Director Appointment
Dhavala Madhavi was appointed as a Managing Director was appointed as a Managing Director on 15 Jul 2011 & has been associated with this company since 13 years 7 months .
Frequently asked questions
What is the Incorporation or founding date of Genome Therapeutics Private Limited?
Genome Therapeutics Private Limited was incorporated on 15 Jul 2011.
What is authorized share capital and paid-up capital of Genome Therapeutics Private Limited?
The authorized share capital of Genome Therapeutics Private Limited is ₹ 1.00 M and paid-up capital is ₹ 1.00 M.
Who are the current board members & directors of Genome Therapeutics Private Limited?
Currently 2 directors are associated with Genome Therapeutics Private Limited.
- Ravimohan Dhavala
- Dhavala Madhavi
What is the registered address of Genome Therapeutics Private Limited?
As per Ministry of Corporate Affairs (Mca), the registered address of Genome Therapeutics Private Limited is H.No: 1-18-76/1/F2 Vijay Residency, Mes Colony Venkatapuram India, Secunderabad, Telangana, 500015.
What is the corporate identification number (CIN) and company number of Genome Therapeutics Private Limited?
The corporate identification number (CIN) of Genome Therapeutics Private Limited is U24232TG2011PTC075543 and the company number is 075543 as per Ministry of Corporate Affairs (MCA).
What has been the recent revenue trend for Genome Therapeutics Private Limited?
According to the financial reports for the fiscal year 2020, the revenue trend for Genome Therapeutics Private Limited has risen by 0.89%.
What change has been observed in the net worth of Genome Therapeutics Private Limited, and by what percentage?
The financial reports for the fiscal year 2020 indicates that The net worth of Genome Therapeutics Private Limited has experienced an upsurge of 27.81%.
What are the total open charges for Genome Therapeutics Private Limited?
As per the financial statements for fiscal Year 2020, The total open charges for Genome Therapeutics Private Limited amount to ₹ 6.30 M.
When was the last Balance Sheet of Genome Therapeutics Private Limited filed with the ROC?
The most recent Balance Sheet for Genome Therapeutics Private Limited was filed with the ROC on 31 Mar 2024.
People also Viewed
SA
Suman AravetiDirectorDS
Dhavala SarmaDirector
Similar Companies Based on Pharmaceutical Retailers & Distributors
Wellness Forever Medicare Limited Mumbai, Maharashtra, India
Sun Pharma Distributors Limited Mumbai, Maharashtra, India
Novartis Healthcare Private Limited Mumbai, Maharashtra, India
Mylan Pharmaceuticals Private Limited Hyderabad, Telangana, India
Msd Pharmaceuticals Private Limited New Delhi, Delhi, India
Aster Dm Healthcare Limited Bangalore, Karnataka, India
Reckitt Benckiser Healthcare India Private Limited Gurugram, Haryana, India
Trident Chemphar Limited Hyderabad, Telangana, India